Key Highlights
- Alignment Healthcare shares are trading up 6.95% today, stabilizing after a multi-week selloff.
- Second-quarter results topped estimates, with adjusted EPS of $0.17 beating the $0.13 estimate.
- Full-year guidance was raised, though the stock had initially sold off on valuation and legal concerns.
- Several analysts trimmed price targets even while maintaining bullish ratings on the stock.
Why Is Alignment Healthcare Stock Rising Today?
Alignment Healthcare (NASDAQ:ALHC) shares are stabilizing today, up nearly 7% after a brutal multi-week selloff triggered by a whistleblower lawsuit alleging the company misclassified $8-10 million in operating expenses to inflate adjusted EBITDA, prompting multiple law firms to investigate potential securities class actions. Despite the legal overhang, the company's Q2 2026 results topped estimates, with adjusted EPS of $0.17 beating the $0.13 expected and revenue up 33.6% year-over-year to $1.336 billion.
Alignment Healthcare is a technology-driven, consumer-centric Medicare Advantage provider founded in 2013 and headquartered in Orange, California, operating more than 30 Medicare Advantage plans spanning six states through its proprietary AVA technology platform.
Weighing the Legal Overhang Against Fundamentals
Despite raising full-year guidance alongside the earnings beat, the stock initially sold off on valuation concerns following its recent sharp price gains and the accounting risk cited in the whistleblower allegations. Raymond James downgraded shares to Outperform from Strong Buy, cutting its price target to $22 from $26, while maintaining a broadly bullish stance even as investors weigh the roughly 40% pullback from recent highs against a still-bullish consensus fair value estimate near $25.
The stabilization today comes against a broader healthcare sector backdrop that has recently outperformed the market, with peers Centene and Eli Lilly (NYSE:LLY) also posting gains this week.
Conclusion
Alignment Healthcare shares are stabilizing today after weeks of pressure tied to whistleblower allegations, even as the company's underlying second-quarter results and raised guidance point to continued operational momentum. Investors appear to be weighing the legal overhang against still-favorable fundamentals as the stock finds its footing.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...